title: WHO classification and WPSS predict posttransplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO).
abstract: We evaluated the impact of World Health Organization (WHO) classification and WHO classification-based Prognostic Scoring System (WPSS) on the outcome of patients with myelodysplastic syndrome (MDS) who underwent allogeneic stem cell transplantation (allo-SCT) between 1990 and 2006. Five-year overall survival (OS) was 80% in refractory anemias, 57% in refractory cytopenias, 51% in refractory anemia with excess blasts 1 (RAEB-1), 28% in RAEB-2, and 25% in acute leukemia from MDS (P = .001). Five-year probability of relapse was 9%, 22%, 24%, 56%, and 53%, respectively (P < .001). Five-year transplant-related mortality (TRM) was 14%, 39%, 38%, 34%, and 44%, respectively (P = .24). In multivariate analysis, WHO classification showed a significant effect on OS (P = .017) and probability of relapse (P = .01); transfusion dependency was associated with a reduced OS (P = .01) and increased TRM (P = .037), whereas WPSS showed a prognostic significance on both OS (P = .001) and probability of relapse (P < .001). In patients without excess blasts, multilineage dysplasia and transfusion dependency affected OS (P = .001 and P = .009, respectively), and were associated with an increased TRM (P = .013 and P = .031, respectively). In these patients, WPSS identified 2 groups with different OS and TRM. These data suggest that WHO classification and WPSS have a relevant prognostic value in posttransplantation outcome of MDS patients.
authors.affiliation: Division of Hematology, University of Pavia, Fondazione Policlinico San Matteo, Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS), Pavia, Italy. alessandrino@smatteo.pv.it
authors.forename: Emilio Paolo
authors.initials: EP
authors.lastname: Alessandrino
authors.forename: Matteo Giovanni
authors.initials: MG
authors.lastname: Della Porta
authors.forename: Andrea
authors.initials: A
authors.lastname: Bacigalupo
authors.forename: Maria Teresa
authors.initials: MT
authors.lastname: Van Lint
authors.forename: Michele
authors.initials: M
authors.lastname: Falda
authors.forename: Francesco
authors.initials: F
authors.lastname: Onida
authors.forename: Massimo
authors.initials: M
authors.lastname: Bernardi
authors.forename: Anna Paola
authors.initials: AP
authors.lastname: Iori
authors.forename: Alessandro
authors.initials: A
authors.lastname: Rambaldi
authors.forename: Raffaella
authors.initials: R
authors.lastname: Cerretti
authors.forename: Paola
authors.initials: P
authors.lastname: Marenco
authors.forename: Pietro
authors.initials: P
authors.lastname: Pioltelli
authors.forename: Luca
authors.initials: L
authors.lastname: Malcovati
authors.forename: Cristiana
authors.initials: C
authors.lastname: Pascutto
authors.forename: Rosi
authors.initials: R
authors.lastname: Oneto
authors.forename: Renato
authors.initials: R
authors.lastname: Fanin
authors.forename: Alberto
authors.initials: A
authors.lastname: Bosi
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001803:Blood Transfusion; D002965:Classification; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation / Q000401:mortality*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000145:classification* / Q000175:diagnosis / Q000628:therapy*; D011379:Prognosis; D012008:Recurrence; D015996:Survival Rate; D014944:World Health Organization